Nexvet's $40M IPO Pricing Adds To Rough Day For Biotechs
Animal medicine developer Nexvet Biopharma PLC priced an initial public offering below range Thursday, raising about $40 million, and watched shares slide further in debut trading, the latest in a flurry...To view the full article, register now.
Already a subscriber? Click here to view full article